^
Association details:
| Biomarker: | FGFR3-TACC3 F17T8 |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | fexagratinib (ABSK091) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.
Published date:
05/16/2018
Excerpt:
All pts with PR had tumors harboring FGFR fusions; one with urothelial transitional cell carcinoma (FGFR3-TACC3 F17T8) and the other with squamous cell carcinoma of cervix (FGFR3-TACC3 F17T11)
DOI:
10.1200/JCO.2018.36.15_suppl.2503
Trial ID:
Source:
Title:
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Excerpt:
Patients who achieved PR harbored the following aberrations: FGFR2 Y376C (n = 1), FGFR3 A393E (n = 1), and FGFR3-TACC3 fusions (n = 2)...Urothelial carcinomas (n = 6) harbored FGFR3 aberrations exclusively (point mutations and fusions)...Confirmed partial responses were seen in 8% (90% CI, 3% to 18%) and were observed only in patients whose tumors harbored FGFR1-3 point mutations or fusions. All objective responses and PR or SD for > 6 months were seen in patients with FGFR mutations or fusions...Clinical Characteristics and Genomic Aberrations of the Patients Who Achieved PR (n = 4) and SD for > 6 months (n = 3).
DOI:
10.1200/JCO.19.02630
